Enveda Raises $311M to Turn Nature's Chemistry Into Metabolic Medicines

Enveda, a Colorado-based biotech founded on the premise that nature's billions of years of chemical evolution outpaces synthetic design, has raised $311 million in a Series E round to push its AI-discovered drug candidates into larger clinical trials. Total capital raised since founding now exceeds $845 million, with backers spanning healthcare specialists, tech-focused funds, and a sovereign wealth fund.

The company's platform, PRISM, works differently from most AI drug-discovery tools. Rather than designing molecules from scratch, it identifies compounds already present in plants, microbes, and the human body by predicting molecular structures from mass spectrometry data, then ranks candidates by therapeutic potential before chemists refine the best into oral medicines. Since 2019, this has produced 17 development candidates, three now in human trials.

The most longevity-relevant candidate is ENV-308, inspired by a molecule the body naturally produces during intense exercise. It is being developed to help people sustain weight loss and metabolic health after discontinuing GLP-1 drugs like semaglutide — a real and growing challenge as millions cycle on and off these medications. In an 88-person trial of healthy volunteers, ENV-308 was well tolerated, with notably few gastrointestinal side effects and measurable reductions in circulating leptin, suggesting it is reaching the intended metabolic biology.

A second clinical-stage candidate, ENV-294, targeting atopic dermatitis and asthma, demonstrated an 85% average improvement in eczema severity after 42 days in an early study. New data is expected at a major dermatology congress later in 2026.

The new capital will fund later-stage trials for ENV-308 and ENV-294, advance a third candidate, ENV-6946, through mid-phase testing, and expand the automated lab feeding PRISM new data. The metabolic health story — preserving healthspan gains from GLP-1 therapy rather than repeatedly chasing them — is the clearest hook for longevity-focused readers, though the platform's breadth suggests more candidates will follow.